SNTI — Senti Biosciences Holdings Share News
0.000.00%
Last trade - 00:00- $5.87m
- $3.40m
- $0.02m
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM
Brief: Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder
Senti Biosciences Q1 net loss narrows on cost reduction
Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
Brief: Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing
Senti Biosciences Q4 revenue misses analyst estimates
Brief: Senti Biosciences Q4 Net Income USD -14.467 Million
Brief: Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202
Cell therapy developer Senti Biosciences' Q3 net loss narrows
Brief: Senti Biosciences Q3 Net Income USD -18.126 Million
U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart
U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart
H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes
Brief: Senti Biosciences Q2 Net Income USD -14.733 Million
Brief: Senti Bio Determines Recommended Phase 2 Dose (RP2D) In Phase 1 Study Of Senti-202
Brief: Senti Biosciences Q1 Net Income USD -14.112 Million
Brief: Senti Bio's SENTI-202, A First-In-Class Off-The-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results In The Treatment Of Patients With Relapsed/Refractory AML
Brief: Senti Biosciences Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing